The granting of a new patent typically strengthens a company's competitive position by protecting its intellectual property, which can lead to increased investor confidence and potential revenue streams from the patented treatment. For Checkpoint Therapeutics, this patent for cosibelimab could be significant in terms of future earnings and market exclusivity, especially in the oncology segment.